Metabolic Associated Fatty Liver Disease
15
6
7
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 15 trials
100.0%
+13.5% vs benchmark
7%
1 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (15)
Glucagon Resistance in Patients With MASLD and T2DM
Metabolic Associated Fatty Liver Disease and Pancreatic Steatosis in Obese Versus Lean Chronic Hepatitis B Patients
Evaluation of Non-Invasive Tests for Metabolic Liver Disease
Benefits of Trimetazidine in MASLD Patients
Effect of Low Valine Diet on Body Weight and Metabolic Parameters
Therapeutic Response of Sodium-glucose Co-transporter Type-2 Inhibitor in Non-diabetic MAFLD Patients: a Pilot Study
Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Clinical Characteristics of Metabolic Associated Fatty Liver Disease
Short Term Outcome of Metabolic Associated Fatty Liver Disease (MAFLD) in Patients Undergoing Bariatric Surgery
Supplementation With Alpha-lipoic Acid and Silybum Marianum(LUDLEV®) for the Improvement of Fatty Liver Disease
Clinical Study of SARS-CoV-2 Vaccine in Metabolism-related Fatty Liver Disease
Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China
Lifestyle Modification for MAFLD Based on TTM
MAFLD-simplified Definition as an Optimized Risk Stratification Tool for Predicting Metabolic Outcomes
A Prospective Cohort Study of Metabolic Associated Fatty Liver Disease in China